ElmetsCALeonardiCLDavidDMR, et al.Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–1113. doi:10.1016/j.jaad.2018.11.057.
2.
MenterAStroberBEKaplanDH, et al.Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4), 1029–1072. doi:10.1016/j.jaad.2018.11.057.
3.
SinghJAGuyattGOgdieA., et al.Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken). 2019;71(1):2–29. doi:10.1002/acr.23789.
4.
ArmstrongAWSiegelMPBagelJ, et al.From the medical board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2019;76(2):290–298. doi:10.1016/j.jaad.2016.10.017.
5.
HaroonMGallagherPFitzGeraldO. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045–1050. doi:10.1136/annrheumdis-2013-204858.
6.
GelfandJMTroxelABLewisJD, et al.The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493–1499. doi:10.1001/archderm.143.12.1493.
7.
NoeMHShinDBWanMTGelfandJM. Objective measures of psoriasis severity predict mortality: a prospective population-based cohort study. J Invest Dermatol;138(1):228–230. doi:10.1016/j.jid.2017.07.841.
8.
ArmstrongAWRobertsonADWuJSchuppCLebwohlMG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation Surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180–1185. doi:10.1001/jamadermatol.2013.5264.
